Literature DB >> 20300922

[Invasive tumor pain therapy in the final stage of a cervix cancer patient].

Adolf Ofenschüssl1, Wilfried Ilias2.   

Abstract

Cancer disease is associated with a lot of very burdening symptoms. Pain is with dyspnea and emesis in the first time in a rate of about 50%, in the terminal stage up to 90% the most tormenting symptom. For more than 90% of patients the 3-step-WHO-regimen for cancer pain is able to relieve pain successfully. But a little group of cancer patients need invasive measures and methods to relieve pain sufficiently. This would be the 4th step, according to the enlarged WHO-regimen. Intravenous or intrathecal applications, eventually regional blockades should be considered. The following case-report shows the steps of a difficult cancer pain therapy in a regional general hospital. It is sometimes not evidence based, on the one hand because of necessary organizational, staff-related, or other makeshifts in daily clinical practice, on the other hand because of the lack of appropriate EBM-guidelines. The pressure to reduce the pain effectively and as simple as possible produces sometimes polypragmatic, retrospective not always satisfying measures.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20300922     DOI: 10.1007/s10354-010-0753-x

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  4 in total

Review 1.  Current evidence for a genetic modulation of the response to analgesics.

Authors:  Jörn Lötsch; Gerd Geisslinger
Journal:  Pain       Date:  2006-02-10       Impact factor: 6.961

2.  [Intravenous S-+-ketamine for treatment of visceral pain in the final phase].

Authors:  Dietmar Weixler; Wolfgang Hartmann
Journal:  Wien Med Wochenschr       Date:  2006-05

Review 3.  [Pain therapy in tumor patients and in palliative medicine. 2: Invasive measures].

Authors:  G G Hanekop; M T Bautz; D Beck; D Kettler; F B Ensink
Journal:  Zentralbl Chir       Date:  1998       Impact factor: 0.942

4.  Opioid rotation for toxicity reduction in terminal cancer patients.

Authors:  N D de Stoutz; E Bruera; M Suarez-Almazor
Journal:  J Pain Symptom Manage       Date:  1995-07       Impact factor: 3.612

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.